|
|
Дата |
|---|
| 20:40 |
| 13.11.2026 |
| 12.11.2026 |
| 11.11.2026 |
| 10.11.2026 |
| 09.11.2026 |
| 06.11.2026 |
| 05.11.2026 |
| 04.11.2026 |
| 03.11.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
3.28
|
3.44
|
3.46
|
3.36
|
3.46
|
3.36
|
|
|
1 173.73
|
11.00
|
|
2.97
|
3.69
|
3.755
|
3.47
|
3.755
|
3.47
|
|
|
3 223.48
|
20.00
|
|
3.46
|
3.88
|
3.96
|
3.68
|
3.96
|
3.72
|
|
|
1 835.19
|
15.00
|
|
3.84
|
5.38
|
4.055
|
3.63
|
4.055
|
3.91
|
|
|
13 073.17
|
72.00
|
|
3.82
|
5.52
|
4.47
|
4.02
|
4.55
|
4.07
|
|
|
95 144.62
|
64.00
|
|
4.39
|
4.80
|
4.365
|
4.365
|
4.80
|
4.53
|
|
|
134 336.43
|
107.00
|
|
4.10
|
5.52
|
4.57
|
4.13
|
4.60
|
4.42
|
|
|
70 448.55
|
79.00
|
|
4.06
|
5.52
|
4.69
|
4.30
|
4.74
|
4.34
|
|
|
42 736.56
|
95.00
|
|
4.10
|
5.48
|
4.90
|
4.53
|
4.90
|
4.53
|
|
|
19 114.26
|
54.00
|
|
4.73
|
4.86
|
4.69
|
4.69
|
4.81
|
4.74
|
|
|
6 548.99
|
35.00
|
LeonaBio, Inc., formerly Athira Pharma, Inc., is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). The Company's lead drug candidates, lasofoxifene and ATH-1105, are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. ATH-1105 is a novel, orally available, brain-penetrant, next-generation small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases, including ALS, Alzheimer's disease, and Parkinson's disease.
Lasofoxifene is a novel, nonsteroidal SERM with a binding profile, designed to confer potent activity against both wild-type and mutant estrogen receptors, including the clinically significant ESR1 mutations.
Показать все Скрыть